Key Points
- Indivior CAO Woodrow Anderson bought 1,500 shares at an average price of $36.28, investing $54,420 and increasing his ownership by 6.09% to 26,138 shares.
- Indivior shares opened at $38.73, with a $4.57 billion market capitalization and a 12-month trading range of $21.48 to $42.81. The company reported quarterly revenue of $343 million and earnings of $5.75 per share.
- Analysts maintain a generally positive outlook, with five Buy ratings and two Holds, producing a consensus “Moderate Buy” rating and a $45.17 price target. Institutional investors own 60.33% of the stock.
Indivior PLC (NASDAQ:INDV - Get Free Report) CAO Woodrow Anderson acquired 1,500 shares of Indivior stock in a transaction that occurred on Wednesday, August 5th. The stock was acquired at an average cost of $36.28 per share, for a total transaction of $54,420.00. Following the purchase, the chief accounting officer owned 26,138 shares of the company's stock, valued at $948,286.64. The trade was a 6.09% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
Indivior Stock Up 6.1%
Shares of NASDAQ:INDV opened at $38.73 on Thursday. The firm has a market cap of $4.57 billion, a P/E ratio of 13.88 and a beta of 0.86. Indivior PLC has a 12-month low of $21.48 and a 12-month high of $42.81. The business has a fifty day simple moving average of $39.18 and a 200 day simple moving average of $35.57.
Indivior (NASDAQ:INDV - Get Free Report) last issued its quarterly earnings results on Tuesday, June 30th. The company reported $5.75 earnings per share for the quarter. Indivior had a negative return on equity of 283.11% and a net margin of 26.65%.The company had revenue of $343.00 million during the quarter.
Institutional Trading of Indivior
A number of institutional investors have recently modified their holdings of INDV. Caitong International Asset Management Co. Ltd increased its position in shares of Indivior by 72.7% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,093 shares of the company's stock worth $39,000 after purchasing an additional 460 shares during the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al lifted its holdings in shares of Indivior by 3.4% during the 4th quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 21,200 shares of the company's stock worth $761,000 after acquiring an additional 700 shares during the last quarter. Blue Trust Inc. grew its position in Indivior by 17.8% in the fourth quarter. Blue Trust Inc. now owns 4,859 shares of the company's stock worth $176,000 after acquiring an additional 733 shares in the last quarter. Harbor Capital Advisors Inc. increased its stake in Indivior by 309.9% in the fourth quarter. Harbor Capital Advisors Inc. now owns 1,033 shares of the company's stock valued at $37,000 after acquiring an additional 781 shares during the last quarter. Finally, Salomon & Ludwin LLC purchased a new stake in Indivior during the fourth quarter valued at about $30,000. 60.33% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
Several research analysts have issued reports on the stock. Craig Hallum restated a "buy" rating and set a $53.00 price target on shares of Indivior in a report on Tuesday. Barclays decreased their price objective on shares of Indivior from $46.00 to $43.00 and set an "overweight" rating for the company in a research report on Wednesday. Weiss Ratings raised shares of Indivior from a "hold (c)" rating to a "hold (c+)" rating in a research note on Friday, July 24th. Finally, Zacks Research downgraded Indivior from a "strong-buy" rating to a "hold" rating in a report on Monday, June 29th. Five equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $45.17.
Check Out Our Latest Report on Indivior
Indivior Company Profile
(
Get Free Report)
Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company's portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.
Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
